Teva Pharmaceutical (TEVA) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Teva Pharmaceutical (TEVA)

38.10

+1.17 (3.17%)

as of Aug 25, 2026, 8:00:00 pm Market Open.

70 watching

Investor Insights

Aug 25, 2026, 12:00 am

This summary was created by AI, based on 5 opinions in the last 12 months.

Teva Pharmaceutical, currently rated TEVA-N, has gained attention due to a recent credit rating upgrade from Moody's, emphasizing the success of its growth strategy bolstered by key innovative products, a robust pipeline, and ongoing debt reduction. Despite some fluctuations in stock performance and concerns regarding the pharmaceutical sector's competitiveness, especially with generics entering the market, Teva's operational metrics are improving, including revenue diversity and solid free cash flow. The leadership under the current CEO has been particularly transformative, seeing a significant turnaround since early 2023. However, experts highlight mixed sentiments about Teva's innovative capabilities, suggesting caution for investors looking for standout pharmaceuticals. Nonetheless, the stock has shown strong accumulation and resilience in a favorable drug market lately.

Consensus

Positive

Valuation

Fair Value

Similar

Pfizer,PFE

BUY

Largest generic drug manufacturer globally. Had a bit of a correction when the head of its North American operations resigned and was replaced. He has a 2-pronged approach to the drug industry. This is his growth generic company and he owns Pfizer (PFE-N) as his value dividend play.

PAST TOP PICK

(A Top Pick Jan 9/07. Up 45,7%.) World’s largest generic drug manufacturer. Has been a major beneficiary of the majors losing patents. Still buying.

TOP PICK

A long time favourite. It is the largest generic pharmaceutical company. They will be able to benefit from the aging population and government wanting more generic prescriptions. He bought this stock in the low 30's.

BUY

The best company to own in the generics drug area.

TOP PICK

Sitting by its all-time high even in this poor market. Largest generic drug manufacturer in the world. A major beneficiary of an economic slowdown because people will switch from branded products to generics. Major beneficiary of drugs coming off patent.

PAST TOP PICK

(A Top Pick July 25/06. Up 42%.) Still a Buy. The biggest generic drug manufacturer in the world.

BUY

An Israeli generics pharmaceutical company. At these levels, it is a very interesting stock.

TOP PICK

World's largest generic drug manufacturer. Has gone from being a growth stock to a value stock. A lot more patented drugs will be coming off in 2007 and 2008.

Wealthica Track your Stocks in your Watch List

BUY

World’s largest generic drug manufacturer. Also have their own branded drug division. Made some acquisitions and is going through some digestion, but a year from now the stock should be significantly higher.

BUY

Generic pharmaceutical company. Very well run. Lots of cash.

BUY

World’s largest generic drug manufacturer. A value stock. Has a great pipeline of new drugs coming out in the next few years, both generic and its own proprietary drugs. Pfizer’s (PFE-N) Lipitor drug does not come off patent until 2011.

BUY

World’s largest generic drug manufacturer with most sales in North America. Reported great earnings, but stock has acted poorly lately because next year’s growth is not going to be as big. Good price.

BUY

Generic drugs. Trades and about 16 X earnings. Has a lot of cash on its balance sheet. There is a lot of competition in the generic sector still expects there will be mergers. It should continue to do well.

TOP PICK

World's largest generic drug manufacturer. Gone from being a growth stock to a value stock. Merck and Pfizer have come out with their own generics when their drugs came off patent. Based in Israel. The drop in price gives a good opportunity.

BUY

Largest generic drug manufacturer in the world. Likes long-term outlook for generics. Emerging markets have come off which affected the stock. Bit of a tumult on drugs coming off patent with original patent owners issuing drugs for less than generics. A temporary phenomena and this company will again be on top.

Showing 226 to 240 of 277 entries

Most Recent Experts

Jason Del Vicario

HollisWealth

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Rick Rule

Rule Investment Media

Jim Cramer - Mad Money

CNBC

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Summer Sale

Teva Pharmaceutical (TEVA)